Kamada announced that the FDA has accepted for filing the Biologics License Application (BLA) submitted for intravenous alpha-1 antitrypsin (IV-AAT).  IV-AAT is being developed for the treatment of  alpha-1 antitrypsin deficiency. IV-AAT is a high purity, liquid, ready-to-use human plasma derived AAT, produced by a proprietary chromatographic purification method.

For more information visit www.kamada.com.